<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35285384</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>15</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1525-6049</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>44</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Renal failure</Title>
          <ISOAbbreviation>Ren Fail</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Pifithrin-α ameliorates glycerol induced rhabdomyolysis and acute kidney injury by reducing p53 activation.</ArticleTitle>
        <Pagination>
          <StartPage>473</StartPage>
          <EndPage>481</EndPage>
          <MedlinePgn>473-481</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/0886022X.2022.2048857</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">Rhabdomyolysis is a series of symptoms caused by the dissolution of striped muscle, and acute kidney injury (AKI) is a potential complication of severe rhabdomyolysis. The underlying causes of AKI are remarkably complex and diverse. Here, we aim to investigate whether pifithrin-α protected against rhabdomyolysis-induced AKI and to determine the involved mechanisms.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Intramuscular injection in the right thigh caudal muscle of C57BL/6J mice with 7.5 ml/kg saline (Group A) or of the same volume 50% glycerol was used to induce rhabdomyolysis and subsequent AKI (Group B). Pifithrin-α was injected intraperitoneally 4 h before (Group C) or 4 h after (Group D) the glycerol injection. Serum creatine kinase, blood urea nitrogen, and creatinine were determined, and the renal cortex was histologically analyzed. Renal expression levels of interested mRNAs and proteins were determined and compared, too.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Intramuscular injection of glycerol induced rhabdomyolysis and subsequent AKI in mice (Groups B-D). Renal function reduction and histologic injury of renal tubular epithelial cells were associated with increased p53 activation, oxidative stress, and inflammation. Notably, compared with pifithrin-α rescue therapy (Group D), pretreatment of pifithrin-α (Group C) protected the mice from severe injury more effectively.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Our present study suggests that p53 may be a therapeutic target of AKI caused by glycerol, and the inhibition of p53 can block glycerol-mediated AKI by using pharmacological agents instead of genetic inhibitory approaches, which further supports that p53 played a pivotal role in renal tubular injury when challenged with glycerol.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yuqiang</LastName>
            <ForeName>Chen</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Nephrology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lisha</LastName>
            <ForeName>Zhang</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Emergency, Shanghai Punan Hospital, Pudong New District, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jiejun</LastName>
            <ForeName>Wen</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Nephrology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Qin</LastName>
            <ForeName>Xue</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Nephrology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Niansong</LastName>
            <ForeName>Wang</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Nephrology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Ren Fail</MedlineTA>
        <NlmUniqueID>8701128</NlmUniqueID>
        <ISSNLinking>0886-022X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D052160">Benzothiazoles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016159">Tumor Suppressor Protein p53</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>3FPU23BG52</RegistryNumber>
          <NameOfSubstance UI="D014050">Toluene</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>D213B92S1Y</RegistryNumber>
          <NameOfSubstance UI="C121565">pifithrin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>PDC6A3C0OX</RegistryNumber>
          <NameOfSubstance UI="D005990">Glycerol</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D058186" MajorTopicYN="Y">Acute Kidney Injury</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D052160" MajorTopicYN="N">Benzothiazoles</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005990" MajorTopicYN="N">Glycerol</DescriptorName>
          <QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012206" MajorTopicYN="Y">Rhabdomyolysis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014050" MajorTopicYN="N">Toluene</DescriptorName>
          <QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016159" MajorTopicYN="N">Tumor Suppressor Protein p53</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Rhabdomyolysis</Keyword>
        <Keyword MajorTopicYN="N">acute kidney injury</Keyword>
        <Keyword MajorTopicYN="N">oxidative stress</Keyword>
        <Keyword MajorTopicYN="N">pifithrin-α</Keyword>
      </KeywordList>
      <CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>14</Day>
          <Hour>8</Hour>
          <Minute>41</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35285384</ArticleId>
        <ArticleId IdType="pmc">PMC8928845</ArticleId>
        <ArticleId IdType="doi">10.1080/0886022X.2022.2048857</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Bosch X, Poch E, Grau JM.. 
Rhabdomyolysis and acute kidney injury. N Engl J Med. 2009;361(1):62–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19571284</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Black L, Lever JM, Traylor AM, et al. . 
Divergent effects of AKI to CKD models on inflammation and fibrosis. Am J Physiol Renal Physiol. 2018;315(4):F1107–F1118.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6230746</ArticleId>
            <ArticleId IdType="pubmed">29897282</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He L, Wei Q, Liu J, et al. . 
AKI on CKD: heightened injury, suppressed repair, and the underlying mechanisms. Kidney Int. 2017;92(5):1071–1083.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5683166</ArticleId>
            <ArticleId IdType="pubmed">28890325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sutton TA, Hato T, Mai E, et al. . 
p53 is renoprotective after ischemic kidney injury by reducing inflammation. J Am Soc Nephrol. 2013;24(1):113–124.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3537213</ArticleId>
            <ArticleId IdType="pubmed">23222126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ó hAinmhire E, Humphreys BD.. 
Fibrotic changes mediating acute kidney injury to chronic kidney disease transition. Nephron. 2017;137(4):264–267.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5723252</ArticleId>
            <ArticleId IdType="pubmed">28595180</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fan Y, Xiao W, Li Z, et al. . 
RTN1 mediates progression of kidney disease by inducing ER stress. Nat Commun. 2015;6:7841.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4532799</ArticleId>
            <ArticleId IdType="pubmed">26227493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sanz AB, Santamaria B, Ruiz-Ortega M, et al. . 
Mechanisms of renal apoptosis in health and disease. J Am Soc Nephrol. 2008;19(9):1634–1642.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18632846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fang J, Yao X, Hou M, et al. . 
ApoL1 induces kidney inflammation through RIG-I/NF-κB activation. Biochem Biophys Res Commun. 2020;527(2):466–473.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32336543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen J, Wang J, Li H, et al. . 
p53 activates miR-192-5p to mediate vancomycin induced AKI. Sci Rep. 2016;6:38868.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5150818</ArticleId>
            <ArticleId IdType="pubmed">27941921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zager RA, Johnson ACM.. 
Acute kidney injury induces dramatic p21 upregulation via a novel, glucocorticoid-activated, pathway. Am J Physiol Renal Physiol. 2019;316(4):F674–F681.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6483029</ArticleId>
            <ArticleId IdType="pubmed">30698046</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou L, Fu P, Huang XR, et al. . 
Activation of p53 promotes renal injury in acute aristolochic acid nephropathy. JASN. 2010;21(1):31–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2799275</ArticleId>
            <ArticleId IdType="pubmed">19892935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang L, Besschetnova TY, Brooks CR, et al. . 
Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat Med. 2010;16(5):535–543.143.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3928013</ArticleId>
            <ArticleId IdType="pubmed">20436483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peng J, Li X, Zhang D, et al. . 
Hyperglycemia, p53, and mitochondrial pathway of apoptosis are involved in the susceptibility of diabetic models to ischemic acute kidney injury. Kidney Int. 2015;87(1):137–150.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4276728</ArticleId>
            <ArticleId IdType="pubmed">24963915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen YL, Sun L, Hu YJ, et al. . 
P53 inhibitor pifithrin-alpha prevents the renal tubular epithelial cells against injury. Am J Transl Res. 2016;8(10):4040–4053.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5095300</ArticleId>
            <ArticleId IdType="pubmed">27829991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Higgins SP, Tang Y, Higgins CE, et al. . 
TGF-β1/p53 signaling in renal fibrogenesis. Cell Signal. 2018;43:1–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5860677</ArticleId>
            <ArticleId IdType="pubmed">29191563</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim JH, Lee DW, Jung MH, et al. . 
Macrophage depletion ameliorates glycerol-induced acute kidney injury in mice. Nephron Exp Nephrol. 2014;128(1-2):21–29.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25376384</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uchida A, Kidokoro K, Sogawa Y, et al. . 
5-Aminolevulinic acid exerts renoprotective effect via Nrf2 activation in murine rhabdomyolysis-induced acute kidney injury. Nephrology (Carlton). 2019;24(1):28–38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29068550</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu J, Li K, He Y, et al. . 
Anticubilin antisense RNA ameliorates adriamycin-induced tubulointerstitial injury in experimental rats. Am J Med Sci. 2011;342(6):494–502.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22108171</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rangan GK, Pippin JW, Coombes JD, et al. . 
C5b-9 does not mediate chronic tubulointerstitial disease in the absence of proteinuria. Kidney Int. 2005;67(2):492–503.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15673297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tan HL, Yap JQ, Qian Q.. 
Acute kidney injury: tubular markers and risk for chronic kidney disease and End-Stage kidney failure. Blood Purif. 2016;41(1-3):144–150.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26764483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ramesh G, Ranganathan P.. 
Mouse models and methods for studying human disease, acute kidney injury (AKI). Methods Mol Biol. 2014;1194:421–436.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25064118</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhong F, Wang W, Lee K, et al. . 
Role of C/EBP-α in adriamycin-induced podocyte injury. Sci Rep. 2016;6:33520.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5028749</ArticleId>
            <ArticleId IdType="pubmed">27644413</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiao W, Fan Y, Wang N, et al. . 
Knockdown of RTN1A attenuates ER stress and kidney injury in albumin overload-induced nephropathy. Am J Physiol Renal Physiol. 2016;310(5):F409–F415.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4773829</ArticleId>
            <ArticleId IdType="pubmed">26739891</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu J, Singh M, Selivanova G, et al. . 
Pifithrin-α alters p53 post-translational modifications pattern and differentially inhibits p53 target genes. Sci Rep. 2020;10(1):1049.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6978515</ArticleId>
            <ArticleId IdType="pubmed">31974452</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Strausser SA, Nakano D, Souma T.. 
Acute kidney injury to chronic kidney disease transition: insufficient cellular stress response. Curr Opin Nephrol Hypertens. 2018;27(4):314–322.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29702491</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Selewski DT, Hyatt DM, Bennett KM, et al. . 
Is acute kidney injury a harbinger for chronic kidney disease?
Curr Opin Pediatr. 2018;30(2):236–240.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5897901</ArticleId>
            <ArticleId IdType="pubmed">29389682</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fu Y, Tang C, Cai J, et al. . 
Rodent models of AKI-CKD transition. Am J Physiol Renal Physiol. 2018;315(4):F1098–F1106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6230729</ArticleId>
            <ArticleId IdType="pubmed">29949392</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanaka S, Tanaka T, Nangaku M.. 
Hypoxia as a key player in the AKI-to-CKD transition. Am J Physiol Renal Physiol. 2014;307(11):F1187–1195.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25350978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arai S, Kitada K, Yamazaki T, et al. . 
Apoptosis inhibitor of macrophage protein enhances intraluminal debris clearance and ameliorates acute kidney injury in mice. Nat Med. 2016;22(2):183–193.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26726878</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Venkatachalam MA, Weinberg JM, Kriz W, et al. . 
Failed tubule recovery, AKI-CKD transition, and kidney disease progression. J Am Soc Nephrol. 2015;26(8):1765–1776.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4520181</ArticleId>
            <ArticleId IdType="pubmed">25810494</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goldstein SL, Jaber BL, Faubel S; Acute Kidney Injury Advisory Group of American Society of Nephrology, et al.. 
Acute kidney injury advisory group of american society of N. AKI transition of care: a potential opportunity to detect and prevent CKD. Clin J Am Soc Nephrol. 2013;8(3):476–483.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23471414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Petejova N, Martinek A.. 
Acute kidney injury due to rhabdomyolysis and renal replacement therapy: a critical review. Crit Care. 2014;18(3):224.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4056317</ArticleId>
            <ArticleId IdType="pubmed">25043142</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
